Silverback Therapeutics is halting the company’s clinical oncology programs and letting go of about 27% of its workforce as part of a restructuring initiative that would leave Silverback with more cash reserves.
Sage Therapeutics ended two late-stage studies of the depression drug zuranolone after discussions with the U.S. Food and Drug Administration led the company to believe they were unnecessary for potential regulatory approval.
